KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Equity Ratio (2016 - 2026)

Pfizer has reported Equity Ratio over the past 18 years, most recently at 0.43 for Q1 2026.

  • Quarterly Equity Ratio fell 0.58% to 0.43 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.43 through Mar 2026, down 0.58% year-over-year, with the annual reading at 0.42 for FY2025, 0.17% changed from the prior year.
  • Equity Ratio was 0.43 for Q1 2026 at Pfizer, up from 0.42 in the prior quarter.
  • Over five years, Equity Ratio peaked at 2.26 in Q4 2022 and troughed at 0.39 in Q4 2023.
  • The 5-year median for Equity Ratio is 0.44 (2025), against an average of 0.55.
  • Year-over-year, Equity Ratio surged 190.76% in 2022 and then crashed 79.98% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.49 in 2022, then fell by 19.03% to 0.39 in 2023, then increased by 5.2% to 0.41 in 2024, then increased by 0.17% to 0.42 in 2025, then rose by 4.27% to 0.43 in 2026.
  • Per Business Quant, the three most recent readings for PFE's Equity Ratio are 0.43 (Q1 2026), 0.42 (Q4 2025), and 0.45 (Q3 2025).